A Prospective and Exploratory Clinical Study of Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL
Latest Information Update: 01 Aug 2025
At a glance
- Drugs Orelabrutinib (Primary) ; Polatuzumab vedotin (Primary) ; Pomalidomide (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 01 Aug 2025 New trial record